Star Therapeutics recently announced new financing totaling $125 million that will help the San Francisco-based biotechnology company continue to develop their investigational von Willebrand disease therapy VGA039. The U.S. Food and Drug…
Experts: Ming Y. Lim1, Peter Kouides2, Magdalena D. Lewandowska3, Jonathan C. Roberts4,5, Amy Dunn6 Affiliations:1Utah Center for Bleeding & Clotting Disorders at University of Utah Health, Salt Lake…
CHAPTER 1 Recommendation on the Use and Management of Anti-Tissue Factor Pathway Inhibitors in Hemophilia EXPERTS: Magdalena D Lewandowska MD 1, Janice Staber MD2, Glaivy Batsuli MD3, Rose Bender4…
NATIONAL BLEEDING DISORDERS CLINICAL PRACTICE RECOMMENDATIONS FOR HEMOPHILIA TREATMENT CENTER (HTC) SOCIAL WORKERS RECOMMENDATIONS FOR THE ROLE OF SOCIAL WORKERS IN HEMOPHILIA TREATMENT CENTERS IN THE UNITED STATES…
Tyler Hoffman is the donor engagement manager at National Bleeding Disorders Foundation where he manages the donor database, supports business processes and helps the development department. With a background in database management and skilled in…
Nurses and health care providers recommend Emergency Medical Identification (EMI) such as Medic Alert for children of all ages with hemophilia and other bleeding disorders, but most are unsure of what type should be used and where they should be…
The THSNA Summit is a collaboration of the 13 leading non-profit organizations in the fields of Thrombosis and Hemostasis. The Summit provides a focused forum for over 1,000 attendees with an interest in bleeding and clotting disorders to network,…
NBDF is pleased to inform U.S.-based clinicians and other interested individuals of a new series of virtual educational opportunities organized by our friends at the Irish Haemophilia Society (IHS). The IHS is hosting a series of clinical webinars…